Emerging CAR-T Cell Therapies for T Cell Malignancies: Innovations, Challenges, and Future Directions

Expanding the Horizon of CAR-T Cell Therapy: Present Obstacles and New Strategies for Future CARs in Solid Tumors.

Chimeric antigen receptor (CAR)-T cells are synthetic receptors used for the recognition of specific antigens expressed by reprogrammed T cells for targeting tumors. CAR-T cell therapy has gained remarkable clinical success for the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), lymphoplasmacytic lymphoma (LPL), and primary intraocular lymphoma (PIL). The increasing number of preclinical investigations and clinical trials is focusing on extending CAR-T cell therapy to solid tumors due to its remarkable success in leukemia and lymphoma cancers. However, some limitations of CAR-T therapy still exist, including a lack of targetable antigen diversity, heterogeneous antigen expression, insufficient T-cell trafficking efficiency, and an immunosuppressive tumor microenvironment. This review explores the role of CAR-T cell therapy, current challenges, and emerging solutions for solid tumor malignancies. To overcome the existing limitations of CAR-T cell therapy, innovative strategies, including the optimization of novel CAR vectors with checkpoint inhibitors, have been designed to enhance the antitumor activity of CAR-T cells against solid tumors. It also explores the design of novel CAR-T cells and strategies for improving antitumor activity against solid tumors. Among the emerging strategies, universal CARs and combination approaches with checkpoint inhibitors are especially promising for extending CAR-T therapy to solid tumors.

Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells

The increasing global burden of cancer necessitates innovative therapeutic strategies. Cell therapy represents a major breakthrough in oncology, evolving rapidly from the successful application of chimeric antigen receptor T (CAR-T) cells in hematologic malignancies to a multiplatform landscape characterized by the concurrent development of diverse strategies. Current research focuses on T cell receptor-engineered T (TCR-T) cells, tumor-infiltrating lymphocytes (TILs), gamma delta (γδ) T cells, CAR-natural killer (CAR-NK) cells, CAR-macrophages (CAR-Ms), and various strategies based on dendritic cells (DCs), B cells, and stem cells. The translational paradigm is expanding from the relatively mature field of hematologic malignancies to the more prevalent and mechanistically complex domain of solid tumors. In recent years, this field has exhibited a clear trend toward expansion from autologous therapies to allogeneic “off-the-shelf” platforms. Approaches such as CAR-NK and CAR-natural killer T (CAR-NKT) cell therapies exhibit significant clinical potential because of their low immunogenicity and reduced risk of graft-versus-host disease (GvHD). Concurrently, in vivo engineering technologies that directly deliver CAR genes in situ are emerging as promising approaches to lower costs and simplify manufacturing by bypassing complex ex vivo procedures. This review systematically outlines recent advances in these strategies, focusing on their mechanisms of action, target antigens, and clinical translation. Despite progress, formidable challenges remain, including tumor heterogeneity, the immunosuppressive tumor microenvironment (TME), and therapy-related toxicity. To address these challenges, future research will focus on novel target discovery, enhanced toxicity management, and scalable manufacturing processes. The integration of multidisciplinary technologies, such as multiomics analysis, artificial intelligence, and synthetic biology, will advance cell therapies toward safer, more effective, and widely accessible applications.

A guide to CAR T cell therapies: development, current status and future prospects.

Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future Directions.

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematological malignancies; however, its clinical translation to solid tumors, including colon cancer, remains challenging. This review comprehensively examines the current landscape of CAR-T cell therapy for colon cancer, focusing on its underlying mechanisms, recent clinical advances, major challenges, and future perspectives. We provide an overview of CAR-T therapy, highlighting its significance in colorectal cancer and comparing its clinical performance in hematological malignancies and solid tumors. The review discusses the structural design and functional evolution of CAR-T cells, with particular emphasis on tumor-associated antigens such as epidermal growth factor receptor (EGFR), mucin-1 (MUC1), carcinoembryonic antigen (CEA), and Frizzled receptors. Mechanistic insights into the immunosuppressive tumor microenvironment and its impact on CAR-T cell efficacy are also presented. Despite promising preclinical and early clinical outcomes, several barriers continue to limit therapeutic success, including antigen heterogeneity, immune evasion, T-cell exhaustion, poor tumor infiltration, and manufacturing complexities. Current clinical trials targeting CEA, EGFR, and other emerging antigens are critically discussed to highlight recent progress and remaining limitations. In addition, we summarize emerging strategies to enhance CAR-T efficacy, including tumor microenvironment modulation, biomarker-guided patient selection, next-generation CAR designs, and combination therapies. Finally, we discuss future directions for optimizing CAR-T therapy through precision immunotherapy approaches, improved biomarker integration, and well-designed clinical trials. Overall, this review highlights the transformative potential of CAR-T cell therapy in colon cancer while providing a critical perspective on the challenges and opportunities that will shape its future clinical application.

Reprogramming CAR-T Cell Therapy for Solid Tumors: Combination Strategies to Overcome Resistance

Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented clinical success in hematologic malignancies, yet translating these outcomes to solid tumors has proven substantially more challenging. Unlike blood cancers, solid tumors present multiple interconnected barriers, including antigen heterogeneity, inefficient trafficking and infiltration, physical stromal constraints, metabolic competition, and profoundly immunosuppressive tumor microenvironments that collectively limit CAR-T cell persistence and function. Increasing evidence indicates that no single engineering modification is sufficient to overcome these obstacles, driving the development of combination strategies that integrate CAR-T cells with immune checkpoint blockade, cytokine and chemokine modulation, targeted therapies, radiotherapy, oncolytic viruses, cancer vaccines, biomaterial-based delivery platforms, and next-generation synthetic biology approaches. Concurrent advances in armored CAR-T cells, logic-gated circuits, multi-antigen targeting systems, and non-viral gene engineering are enabling more precise, adaptable, and controllable cellular therapies. In this review, we examine the biological mechanisms underlying resistance to CAR-T therapy in solid tumors and critically evaluate emerging combination strategies designed to enhance tumor recognition, trafficking, persistence, and antitumor activity. We further discuss translational challenges, including manufacturing complexity, toxicity management, and patient selection, and propose a framework for developing precision combination CAR-T therapies tailored to the unique biology of individual tumors. Collectively, these advances are reshaping CAR-T cell therapy from a single-agent cellular intervention into a programmable, increasingly integrated platform for solid-tumor immunotherapy.

Beyond Conventional CARs: Expanding the Targetable Antigen Landscape in CAR-T Cell Therapy.

Chimeric antigen receptor (CAR)-T cell therapy has emerged as a central pillar of immunotherapy, with astonishing achievements in the treatment of CD19-positive B cell malignancies and multiple myeloma. In recent years, substantial efforts have been made to translate CAR-T cell therapy into other hematologic malignancies, solid tumors, and also non-malignant disorders, such as autoimmune diseases. Nonetheless, several challenges constrain the broader application of CAR-T cell therapy. Conventional CARs can only recognize extracellular protein antigens, which severely limits the range of targetable antigens. Moreover, extracellular disease-associated proteins are often shared with healthy cells, increasing the risk of on-target, off-tumor toxicities. Consequently, expanding the targetable antigen repertoire in parallel with reducing off-tumor toxicities has become a focus of current research. This review aims to provide a comprehensive overview of recent advances in the design of innovative CAR architectures to expand the targetable antigen landscape. In this regard, we discuss innovative CARs in four main categories: I) peptide-MHC-targeting CARs capable of recognizing intracellular proteins; II) Ultra-precision CARs capable of recognizing pathogenic cells while sparing healthy counterparts; III) Ligand/receptor-based CARs; IV) Non-protein antigen-targeting CARs.